Zobrazeno 1 - 10
of 146
pro vyhledávání: '"R. D. Blumenthal"'
Publikováno v:
Anticancer research. 23(6C)
Radioimmunotherapy (RAIT) has been shown to enhance the efficacy of chemotherapy in a variety of tumor models. When multiple drugs are available for a given tumor type, several questions arise, such as how one selects the appropriate drug to be used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9c2a1ae40665ef63942fb978452c9dbf
https://pubmed.ncbi.nlm.nih.gov/14981904
https://pubmed.ncbi.nlm.nih.gov/14981904
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(10)
Inhibition of the enzyme cyclooxygenase with celecoxib is cytotoxic in a variety of solid tumor cell lines. Previous work has shown that by charting circadian rhythms, it has been possible to find optimal times to deliver a dose of drug, such that it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4b0a0c09ed95b9c9f5fab5a8b361f3ae
https://pubmed.ncbi.nlm.nih.gov/11595712
https://pubmed.ncbi.nlm.nih.gov/11595712
Autor:
T M, Behr, R D, Blumenthal, S, Memtsoudis, R M, Sharkey, S, Gratz, W, Becker, D M, Goldenberg
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(12)
There is currently no method to cure patients with disseminated colorectal cancer, which is the third leading cancer killer in the Western World. This report shows that the GW-39 intrapulmonary micrometastatic human colonic cancer model in nude mice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4c7cc118ac089bfd444cd110a1e5087b
https://pubmed.ncbi.nlm.nih.gov/11156250
https://pubmed.ncbi.nlm.nih.gov/11156250
Publikováno v:
Cancer. 88(2)
During the recovery period after anticancer myelosuppressive therapy, hematopoietic progenitor cells become mitotically active in order to replenish the bone marrow compartment and remain hyperproliferative even after normalization of peripheral whit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::415237d5e31417165bf1748c6d11f91e
https://pubmed.ncbi.nlm.nih.gov/10640965
https://pubmed.ncbi.nlm.nih.gov/10640965
Autor:
T M, Behr, G, Sgouros, M G, Stabin, M, Béhé, C, Angerstein, R D, Blumenthal, C, Apostolidis, R, Molinet, R M, Sharkey, L, Koch, D M, Goldenberg, W, Becker
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
Usually, the red marrow (RM) is the first dose-limiting organ in radioimmunotherapy. However, several studies have obtained only poor correlations between the marrow doses and the resulting toxicities. Furthermore, RM doses are mostly not determined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c171ee888c56344ada50676a58580b56
https://pubmed.ncbi.nlm.nih.gov/10541340
https://pubmed.ncbi.nlm.nih.gov/10541340
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
Nine radioimmunotherapy (RAIT)-naive patients with medullary thyroid cancer received high doses of 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody (232-486 mCi), five in combination with bone marrow harvest, without prior granuloc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::50213ce959230bbedd1e0d94ce9f530b
https://pubmed.ncbi.nlm.nih.gov/10541383
https://pubmed.ncbi.nlm.nih.gov/10541383
Autor:
T M, Behr, A L, Salib, T, Liersch, M, Béhé, C, Angerstein, R D, Blumenthal, A, Fayyazi, R M, Sharkey, B, Ringe, H, Becker, B, Wörmann, W, Hiddemann, D M, Goldenberg, W, Becker
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
At the time of surgery, occult metastases (micrometastases) are present in more than 50% of colorectal cancer patients, and the liver is the most frequent site of apparent metastatic disease. Frequently, adjuvant chemotherapy is unable to prevent tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2d4cda7543f19d67b59dd55675601652
https://pubmed.ncbi.nlm.nih.gov/10541369
https://pubmed.ncbi.nlm.nih.gov/10541369
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 40(10)
This study was undertaken to determine the factors affecting myelotoxicity after radioimmunotherapy (RAIT) with 131I-labeled anticarcinoembryonic antigen (anti-CEA) monoclonal antibodies (MAbs).Ninety-nine patients who received 131I-labeled MN-14 or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::948ec74bfaa32cce46de8374f3257bbe
https://pubmed.ncbi.nlm.nih.gov/10520699
https://pubmed.ncbi.nlm.nih.gov/10520699
Publikováno v:
British Journal of Cancer. 99:837-838
In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c97e9bca8b0531c9408df288c70de002
https://doi.org/10.1038/sj.bjc.6604548
https://doi.org/10.1038/sj.bjc.6604548
Publikováno v:
Experimental hematology. 26(9)
Myelosuppression is the dose-limiting side effect of most forms of radioimmunotherapy (RAIT). Long-term leukopenia (4-8 weeks) has been documented from a single maximum tolerated dose (MTD) in experimental mice. Several methods for alleviating RAIT-i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::77ed15f052279624da1c8514e36bf553
https://pubmed.ncbi.nlm.nih.gov/9694507
https://pubmed.ncbi.nlm.nih.gov/9694507